Kenneth Gordon to Drug Substitution
This is a "connection" page, showing publications Kenneth Gordon has written about Drug Substitution.
Connection Strength
0.481
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am J Clin Dermatol. 2024 Sep; 25(5):795-810.
Score: 0.214
-
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328.
Score: 0.140
-
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
Score: 0.127